Nektar Therapeutics
Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $35.91
- 52-Week Range
- $33.40 – $109.00
- Market Cap
- $1.18B
- P/E (TTM)
- —
- EPS (TTM)
- -22.47
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.39
- PEG Ratio
- 0.31
- Return on Equity
- -37.92%
- Return on Assets
- -14.79%
- Gross Margin
- 100.00%
- Operating Margin
- -303.57%
- Profit Margin
- 0.00%
- Current Ratio
- 9.00
- Debt/Equity
- 0.15
- Total Debt
- $128.67M
- Free Cash Flow
- $-152.10M
- Revenue Growth
- -20.40%
- Earnings Growth
- —
- Enterprise Value
- $691.98M
Market Snapshot
About
Nektar Therapeutics is a biopharmaceutical company developing innovative therapies in immuno-oncology and immunology using its proprietary drug platform technologies. The company focuses on polymer conjugate technology to modify and optimize drug candidates. Nektar has multiple clinical-stage programs aimed at treating cancer and autoimmune diseases.